CD274 and non-small cell lung carcinoma: The pooled results of efficacy by PD‐L1 expression in both SQ and non‐SQ NSCLC patients were consistent with those of the individual reports (ONO‐4538‐05, ONO‐4538‐06).9, 10 The 3‐year OS and PFS rates showed that, after 3 years of follow‐up, nivolumab continued to demonstrate long‐term efficacy in previously treated patients with SQ or non‐SQ NSCLC.